Navigation Links
Results of the AIDA STEMI MRI sub-study presented at TCT 2012
Date:10/25/2012

MIAMI, FL OCTOBER 25, 2012 A study confirmed no differences in various measures of heart damage, according to cardiac magnetic resonance (MRI) imaging, in patients receiving the anti-clotting medication abxicimab directly into the heart (intracoronary) compared to those receiving it intravenously (IV). The results of the AIDA STEMI MRI sub-study were presented today the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation, TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.

The AIDA STEMI trial was a randomized, open-label, multicenter trial in 2,065 patients presenting with ST-elevation myocardial infarction (STEMI) comparing intracoronary (IC) versus intravenous (IV) abciximab during PCI with subsequent 12 hour intravenous infusion. Last year, researchers reported that the trial found that both methods yielded similar 90-day rates of all-cause mortality, recurrent heart attack or congestive heart failure.

Researchers enrolled 703 patients within the overall trial in a cardiac magnetic resonance imaging sub-study, one of the largest MRI sub-studies conducted in patients with STEMI. Cardiac MRI allows for a more sensitive investigation of the mechanistic and pathophysiological effects of STEMI therapies on myocardial damage and reperfusion injury.

Cardiac MRI was completed within four days after heart attack using a standardized protocol including edema imaging and late gadolinium enhancement. Researchers examined infarct size, myocardial salvage, microvascular obstruction and ventricular function to determine the potential benefits of intracoronary compared to intravenous application of abciximab.

The amount of myocardium at risk and final infarct size did not differ significantly between the IC versus the IV abciximab groups. Consequently, the myocardial salvage index was similar between the
'/>"/>

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Results of the PC trial presented at TCT 2012
2. Results of the POSEIDON trial presented at TCT 2012
3. 1-year results of ADAPT-DES presented at TCT 2012
4. Comparison of Obesity Surgeries Turns Up Surprising Results
5. Results from study of Mead Johnsons Enfamil® Human Milk Fortifier Acidified Liquid published in Pediatrics
6. Missed Diagnoses in ICU Often Have Deadly Results: Review
7. Anti-clotting drugs yield similar results
8. Late-Night Cramming May Hurt School Test Results
9. New survey: Women want to SEE breast reconstruction results before cancer surgery
10. Weight-loss surgery results in positive changes in social life, medical conditions
11. Many Test Results Left Unread as Patients Leave Hospital: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... 30, 2015 , ... Between 2012 and 2014 HIV infection rates rose from ... on June 17th. Those untreated heroin use disorders share their needles and spread the ... needles throughout the community. Ultimately Florida’s HIV infection rates have bolstered to 23 percent ...
(Date:7/30/2015)... ... 30, 2015 , ... Ocean Hills Recovery has officially been accredited by CARF ... No recommendations means CARF found no areas in the OHR program that needed improvement, ... of all facilities receive. In addition, Ocean Hills was granted the maximum certification period ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... Administration (DEA) Acting Administrator Chuck Rosenberg’s announcement of the reinstitution of National Prescription ... Saturday, September 26, 2015 from 10:00 AM to 2:00 PM local time. On ...
(Date:7/30/2015)... ... July 30, 2015 , ... The Tisch Cancer ... Designation , The Tisch Cancer Institute (TCI) at the Icahn School of Medicine ... TCI joins an elite group of 69 cancer institutions nationwide that have earned ...
(Date:7/30/2015)... , ... July 30, 2015 , ... InventHelp, ... Texas, has designed a personal-care device that makes it easy to apply lotion or ... eliminate the need for assistance when applying lotion or medication to the back, and ...
Breaking Medicine News(10 mins):Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 2Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 3Health News:Ocean Hills Recovery Receives Accreditation from CARF International 2Health News:AAPCC Supports National Prescription Drug Take-Back Day 2Health News:AAPCC Supports National Prescription Drug Take-Back Day 3Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 2Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 3Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 4Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 5Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 6Health News:InventHelp® Client Patents “My Back Buddy” – Device Could Apply Lotion to Hard-to-Reach Areas Easily 2
... been characterized as the most materialistic generation in history: ... owning luxury handbags and the latest technology devices. ... of teen materialism. In fact, research suggests that parents ... therefore, highly materialistic parents and peers are likely to ...
... ... headquartered in Nashville must pay $19.4 million plus interest to the United States government after ... , ... 2010 -- United States District Court Judge William J. Haynes, Jr. issued an order on ...
... ... Center School of Medicine has designed a first-of-its-kind program to alleviate ... Track (FMAT), has been approved by the Liaison Committee for Medical ... will complete their training one year earlier than students in the ...
... ... a new effort by Congress to reduce pharmacy choices, arbitrarily set prices, ... program. FEHBP enrollees feel that OPM does a great job managing ... the program by forcing OPM to change FEHBP’s pharmacy benefits. This was ...
... for some patients with operable disease, review finds , ... for patients with operable non-small cell lung cancer, say ... meta-analysis of 34 studies involving almost 8,500 patients (and ... years was 64 percent for patients who had chemotherapy ...
... Tuesday, President Obama signed into law U.S. health care ... affect them, their families, and businesses. The ... 2006 legislation in Massachusetts requiring all adults in the ... mandate. A new article from The Milbank Quarterly ...
Cached Medicine News:Health News:Counteracting teens' logo lust 2Health News:Fresenius Medical Holdings, Inc. Ordered To Pay $19.4 Million For Fraudulent Medicare Claims 2Health News:Fresenius Medical Holdings, Inc. Ordered To Pay $19.4 Million For Fraudulent Medicare Claims 3Health News:Primary Care Physician Shortage: Texas Tech University Health Sciences Center Has the Solution 2Health News:Primary Care Physician Shortage: Texas Tech University Health Sciences Center Has the Solution 3Health News:Primary Care Physician Shortage: Texas Tech University Health Sciences Center Has the Solution 4Health News:PCMA: Federal Enrollees Don't Want Congress to Reduce Pharmacy Choices, Impose Price Controls in FEHBP 2Health News:Chemo May Boost Survival After Lung Cancer Surgery 2Health News:Massachusetts health care reform reviewed as a model for national plan 2
(Date:7/29/2015)... 2015  Astellas today announced topline results from ... and safety of intravenous (IV) and oral isavuconazole, ... for adults with candidemia and other invasive ... that the trial did not meet its primary ... isavuconazole-treated patients at the end of IV therapy ...
(Date:7/29/2015)... -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial ... Wednesday, August 5, 2015, after the close of U.S.-based financial ... will host a conference call to review the results beginning ... The press release and a live audio-only ... link that is posted on the home page and Investor ...
(Date:7/29/2015)... July 29, 2015 Unilife Corporation (NASDAQ: ... manufacturer and supplier of injectable drug delivery systems, ... of instant patch pumps for insulin. ... insulin pump that does not require filling or ... and pre-assembled like an insulin pen, only three ...
Breaking Medicine Technology:Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 2Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 3Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 4Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 5Nektar to Announce Financial Results for the Second Quarter 2015 on Wednesday, August 5, 2015, After Close of U.S.-Based Financial Markets 2Nektar to Announce Financial Results for the Second Quarter 2015 on Wednesday, August 5, 2015, After Close of U.S.-Based Financial Markets 3Unilife Introduces World's First Instant Patch Pump for Insulin 2Unilife Introduces World's First Instant Patch Pump for Insulin 3Unilife Introduces World's First Instant Patch Pump for Insulin 4
... March 16 ViroPharma Incorporated (Nasdaq: VPHM ) announced today that the company will provide a live audio webcast of its investor day event, focusing on Cinryze ... ... ... ...
... and ATLANTA , March 15 ... announced results from an analysis of one-year subset data ... diabetes on clinical and angiographic outcomes in heart attack ... Stent System or the Express® bare-metal stent.  The results ...
Cached Medicine Technology:ViroPharma To Host Investor Day 2ViroPharma To Host Investor Day 3ViroPharma To Host Investor Day 4ViroPharma To Host Investor Day 5Study Shows Superior Efficacy for TAXUS(R) Express(R) Stents at One Year Compared to Bare-Metal Stents in Diabetic Patients Experiencing Heart Attack 2Study Shows Superior Efficacy for TAXUS(R) Express(R) Stents at One Year Compared to Bare-Metal Stents in Diabetic Patients Experiencing Heart Attack 3Study Shows Superior Efficacy for TAXUS(R) Express(R) Stents at One Year Compared to Bare-Metal Stents in Diabetic Patients Experiencing Heart Attack 4Study Shows Superior Efficacy for TAXUS(R) Express(R) Stents at One Year Compared to Bare-Metal Stents in Diabetic Patients Experiencing Heart Attack 5Study Shows Superior Efficacy for TAXUS(R) Express(R) Stents at One Year Compared to Bare-Metal Stents in Diabetic Patients Experiencing Heart Attack 6
... Lensmeter is designed for fast and easy ... Auto mode, the readings are automatically held ... lenses are automatically detected. The sophisticated alignment ... lens. The TL-2000A has been designed with ...
The Kowa Pro-lll is Kowas' flagship camera....
The new CR6-45NM non-mydriatic retinal camera is an ideal diagnostic tool for ophthalmologists, optometrists and other medical professionals, especially when it comes to detecting and monitoring diab...
FF 450plus IRu Fundus camera with Visupac / System 431. Digital results in all capture modes and unlimited Visupac software....
Medicine Products: